Alnylam Pharmaceuticals stock falls on silencer drug concerns
Alnylam Pharmaceuticals (ALNY) experienced a 6% decline in stock price after AstraZeneca disclosed disappointing results from a Phase 3 clinical trial for an experimental silencer drug targeting ATTR-CM heart condition. The trial, which involved most participants already on a stabilizer drug, showed no significant improvement in patients taking AstraZeneca's drug alongside stabilizers.
This outcome raises concerns about the viability of silencer drugs amidst intensifying competition among pharmaceutical companies in the ATTR-CM treatment market, valued to reach multi-billion dollars.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
